Determination of Scientific Name of Bitter “Qust”: an Important Controversial Plant Source in the Iranian Medicinal Plants Market for Neurological Complications

Background and objectives: Traditional medicine could provide a hopeful area of research to mitigate the suffering of patients. “Qust” is one of the medicinal plants that are mentioned in Persian Medicine (PM) for treatment of neurological diseases. There is diversity within the scientific name of “Qust” in different references. Some have introduced Saussurea costus (Falc.) Lipsch. (Asteraceae), while others have presented Costus speciosus (J. Koenig) Sm. (Costaceae) as “Qust”. Since “Qust” is not endemic in Iran, there is difficulty to access to the whole plant for its identification. Hence, this study has aimed to identify available bitter “Qust” which is composed of roots of the plant in the Iranian market. Methods: Macroscopic characters and microscopic properties of powders and transverse sections of specimens with essential oil analysis of the Indian and one of the Iran herbal market samples using chromatography-mass spectrometry (GC-MS) were investigated for identification of bitter “Qust”. Results: Microscopic evaluation showed presence of secretory cavities and their specific size, narrow radial rows of conducting tissue alternating with broad medullary rays in the secondary phloem and xylem, presence of inulin, absence of starch and calcium oxalate crystals in the bitter “Qust” particles. Further, positive response was observed to S. costus identifying test. In the analysis of essential oils, active components of S. costus, such as dehydrocostus lactone, were identified in the examined essential oils. Conclusion: According to the results, it could be concluded that bitter “Qust” in Iran herbal market most probably is S. costus

Preparation of Saussurea costus Traditional Oil and Investigation of Different Parameters for Standardization

Background and objective: Medicinal oils are one of the most common and special dosage forms in oral and topical therapies of Persian medicine (PM). The oil of Saussurea costus (bitter qust) root is prominent topical oil with different applications in PM. In this study, the oil of bitter qust was prepared according to ancient Persian medical texts. Methods: To prepare traditional qust oil, 100 g of the root was soaked in 600 mL aqueous ethanol 25% overnight. The supernatant was then filtered and boiled in 800 g sesame oil until all water was evaporated. The essential oil of the root and volatile components of its traditional oil were extracted using hydro-distillation method in a Clevenger-type apparatus and were analyzed by gas chromatography-mass spectrometry (GC-MS) method. Total phenolics, flavonoids, tannins and polysaccharides were determined by spectrophotometric methods to evaluate the chemical parameters of traditional bitter qust oil.  Results: The content of volatile compounds in both investigated samples was determined (0.5% and 0.1% (v/w), respectively). Dehydrocostus lactone and 1, 3-cyclooctadiene were two similar main compounds in the both analyzed samples. Total phenolics (788.290±0.61 mg/L gallic acid equivalent (GAE)), flavonoids (303.2±2.52 mg/L catechin equivalent (CE)), tannins (23.97±0.52 mg/L GAE) and polysaccharides (9.240±0.13 mg/L dextrose equivalent (DE)) contents were determined. Conclusion: According to the obtained data, dehydrocostus lactone could be used for determination and evaluation of traditional bitter qust   oil

The potential of plant-based bioactive compounds on inhibition of aflatoxin B1 biosynthesis and down-regulation of aflR, aflM and aflP genes

The use of plant extracts in pre- and post-harvest disease management of agricultural crops to cope with aflatoxin B1 contamination has shown great promise due to their capability in managing toxins and safe-keeping the quality. We investigated the anti-aflatoxigenic effect of multiple doses of eight plant extracts (Heracleum persicum, Peganum harmala, Crocus sativus, Trachyspermum ammi, Rosmarinus officinalis, Anethum graveolens, Berberis vulgaris, Berberis thunbergii) on Aspergillus flavus via LC-MS and the down-regulatory effect of them on aflR, aflM and aflP genes involved in the aflatoxin B1 biosynthesis pathway using RT-qPCR analyses. Our results showed that H. persicum (4 mg/mL), P. harmala (6 mg/mL) and T. ammi (2 mg/mL) completely stopped the production of aflatoxin B1, without inducing significant changes in A. flavus growth. Furthermore, our findings showed a highly significant correlation between the gene expression and the aflatoxin B1 biosynthesis, such that certain doses of the extracts reduced or blocked the expression of the aflR, aflM and aflP and consequently reduced the synthesis of aflatoxin B1. Interestingly, compared to the regulatory gene (aflR), the down-regulation of expression in the structural genes (aflM and aflP) was more consistent and correlated with the inhibition of aflatoxin B1 production. Overall, this study reveals the anti-aflatoxigenic mechanisms of the selected plant extracts at the gene expression level and provides evidence for their use in plant and crop protection

Effect of Processed Honey and Royal Jelly on Cancer-Related Fatigue: A Double-Blind Randomized Clinical Trial

Background: Cancer-related fatigue (CRF) is experienced by 50% to 90% of cancer patients and can severely affect their quality of life and functional capacity. Several randomized trials have recommended various ways to alleviate the symptoms of CRF with or without recourse to medications. Objective: The aim of this study is to evaluate the effectiveness of processed honey and royal jelly on the symptoms of CRF in cancer patients who are undergoing hormone therapy, chemotherapy, chemo-radiation, or radiotherapy. Methods: Fifty-two participants from the patients who visited the oncology clinic of Shohada-e-Tajrish hospital in Tehran (Iran) between May 2013 and August 2014 were selected and divided into two groups. The study group (26 patients) received processed honey and royal jelly, while the control group received pure honey. Both groups were instructed to consume their 5mL supplement twice daily for 4 weeks. Both groups were assessed at the beginning of the study, after 2 weeks, and then at the end of 4 weeks of treatment. Fatigue was measured using a visual analogue fatigue scale (VAFS) and fatigue severity scale (FSS). The results were compared between the two arms of study, and equality of probability distributions was assessed using a Kolmogorov–Smirnov test. Results: The mean age of the 52 patients was 54.84. After two and four weeks of treatment with processed honey and royal jelly, VAFS and FSS due to treatment was better in the study group than in the control group, and the http://www.ephysician.ir Page 2476 differences were statistically significant (p<0.001, p<0.001, respectively). Conclusion: To the best of our knowledge, our study provided support for the use of processed honey and royal jelly to ameliorate CRF. The positive results of this study warrant further studies in this field. Clinical Trial Registration: The study was registered in the Iranian Clinical Trial Registry Center (http://www.irct.ir) with the registration code: IRCT2015081423426N1. Funding: The authors received no financial support for the research, authorship, and/or publication of this article